Izokibep Demonstrates Clinically Relevant Efficacy Benefits on
Enthesitis, Dactylitis and Nail Outcomes in Active PsA
Patients: A 16-week Randomized, Placebo-controlled Trial

a 2022

Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL et. al.

Basic information

Original name

Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

Authors

DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS

Edition

2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 13.300

RIV identification code

RIV/00216224:14160/22:00128081

Organization unit

Faculty of Pharmacy

ISSN

UT WoS

000877386506127

Keywords in English

izokibep; enthesitis; dactylitis; nail outcomes; clinical trial

Abstract

V originále

PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement. Unresolved enthesitis leads to chronic pain and reduced quality of life1. IL-17 inhibitors have demonstrated benefits across multiple disease features. Izokibep is a unique IL-17A inhibitor with high potency (0.3 pM), small size (18.6 kD) and half-life extending albumin binding. The purpose is to assess the efficacy of izokibep 40 mg Q2W and 80 mg Q2W versus placebo on measures of enthesitis (most common being Leeds Enthesitis Index (LEI), as well as SPARCC), dactylitis and nails, and explore how these disease features impact quality of life (PsAID questionnaire) over 16 weeks. Drug safety was evaluated.

Citovat

DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS. Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial. 2022. ISSN 2326-5191.

@proceedings{2247554,
   author = {De Vlam, Kurt and Taylor, Peter and Mease, Philip J. and Peloso, Paul and Wetzel, Dieter and Brun, Nicolai and Wiens, Brian and BrandtandJuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and Martin, Nadia AbdelandKader and Behrens, Frank},
   keywords = {izokibep; enthesitis; dactylitis; nail outcomes; clinical trial},
   language = {eng},
   title = {Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial},
   year = {2022}
}

TY  - CONF
ID  - 2247554
AU  - De Vlam, Kurt - Taylor, Peter - Mease, Philip J. - Peloso, Paul - Wetzel, Dieter - Brun, Nicolai - Wiens, Brian - Brandt-Juergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Martin, Nadia Abdel-Kader - Behrens, Frank
PY  - 2022
TI  - Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
KW  - izokibep
KW  - enthesitis
KW  - dactylitis
KW  - nail outcomes
KW  - clinical trial
N2  - PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement. Unresolved enthesitis leads to chronic pain and reduced quality of life1. IL-17 inhibitors have demonstrated benefits across multiple disease features. Izokibep is a unique IL-17A inhibitor with high potency (0.3 pM), small size (18.6 kD) and half-life extending albumin binding. The purpose is to assess the efficacy of izokibep 40 mg Q2W and 80 mg Q2W versus placebo on measures of enthesitis (most common being Leeds Enthesitis Index (LEI), as well as SPARCC), dactylitis and nails, and explore how these disease features impact quality of life (PsAID questionnaire) over 16 weeks. Drug safety was evaluated.
ER  -

DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS. \textit{Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial}. 2022. ISSN~2326-5191.

Detailed Information on Publication Record